Dr. Gene Y Im is an Assistant Professor of Medicine in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai. He earned his B.A. from the University of California, Berkeley, graduating with honors. He completed his Internal Medicine residency at Winthrop-University Hospital, the primary teaching affiliate for the SUNY Stony Brook School of Medicine. He continued at Winthrop to complete his fellowship training in Gastroenterology, followed by an advanced fellowship in Transplant Hepatology at the Mount Sinai Medical Center. He has given several oral presentations and presented posters of his research at international meetings such as AASLD, DDW, ACG and NYSGE.
Dr. Im’s areas of clinical interest include cirrhosis, acute/chronic liver diseases, portal hypertension, liver biopsy, quality improvement, inpatient care of liver patients and liver transplantation. His research program focuses on clinical aspects of liver diseases such as alcoholic liver disease, viral hepatitis, portal hypertension, liver biopsy and interpretation and outcomes-based research.
Dr. Im is an UNOS-certified Liver Transplant physician and is board certified in Internal Medicine, Gastroenterology and Transplant Hepatology. He is also a member of the American Association for the Study of Liver Diseases.
Visit RMTI website: www.mountsinaiRMTI.org
American Board of Internal Medicine
Hepatitis C Virus, Liver
MD, New York Medical College
Residency, Internal Medicine
Winthrop University Hospital
Winthrop University Hospital
Fellowship, Transplant Hepatology
Mount Sinai School of Medicine
Outcomes of Inpatient Hospital Transfers to a Liver Transplant Center
The purpose of this study is to examine the characteristics and outcomes of patients referred for inpatient hospital transfer to Mount Sinai Medical Center. These patients anecdotally have poor clinical outcomes, but a systematic evaluation of this special population has not been performed. Multivariate analysis demonstrated that patients with acute on chronic liver failure or sepsis were more likely to have inpatient mortality, P=.03, OR 3.03. This single center experience demonstrates that while inpatient transfers to a liver transplant center lead to successful discharging of <75%, very few evaluations and even fewer liver transplant were performed after transfer, with at least 6 months of follow up. Most of the transferred patients have known liver disease and their rate of inpatient mortality suggests the need for earlier referral to a liver transplant center. Future efforts will focus on a cost-effectiveness analysis of inpatient hospital transfers to the liver service.
Fluid and Tissue Characteristics in Liver Diseases
The purpose of this study is to examine the characteristics of fluid and tissue specimens of patients with liver disease treated at the Mount Sinai Medical Center. Typical fluid specimens include ascites, pleural effusion, blood, cerebrospinal fluid, bronchoalveolar lavage, sputum and urine, etc. Typical tissue specimens include liver tissue obtained by biopsy and transplantation, peritoneum, gallbladder and kidney, etc. This data repository will allow for the study of the natural history of ascites-variants, role of albumin in large volume paracentesis (LVP), outcomes of patients receiving frequent LVP, spontaneous bacterial peritonitis and empyema, liver biopsy charateristics in suspected cirrhosis and after transplantation, and other topics.
Emerging Therapies for Severe Alcoholic Hepatitis
Early liver transplantation for severe alcoholic hepatitis has recently been demonstrated to be a feasible and effective therapy for highly selected patients who fail medical therapy and violate the so-called “6 month rule,” using a rigorous evaluation program. Here at Mount Sinai, we are considering early liver transplantation as a rescue therapy for selected patients with severe alcoholic hepatitis. This is likely one of the first organized experiences with this treatment approach outside of France. Particular areas of interest include patient selection, evaluation, complications, outcomes, burden on organ supply, recidivism and psychosocial evaluation and follow up after transplantation. Translational collaborations are being planned with the Alcoholic Liver Disease Research Center at Mount Sinai to further elucidate the pathogenesis of alcoholic hepatitis. Future clinical trials to evaluate therapies with less side-effects, more targeted therapies or those aimed hepatic regeneration are needed.
Im GY, Sehgal V, Ward SC. A case of undulating fevers and elevated liver tests after pancreas-kidney transplantation. Seminars in liver disease 2013 Feb; 33(1).
Leong J, Im GY. Evaluation and selection of the patient with alcoholic liver disease for liver transplant. Clinics in liver disease 2012 Nov; 16(4).
Im GY, Kazi S, Thung SN, Perumalswami PV. A maxed-out liver: a case of acute-on-chronic liver failure. Seminars in liver disease 2011 Nov; 31(4).
Stavropoulos SN, Im GY, Jlayer Z, Harris MD, Pitea TC, Turi GK, Malet PF, Friedel DM, Grendell JH. High yield of same-session EUS-guided liver biopsy by 19-gauge FNA needle in patients undergoing EUS to exclude biliary obstruction. Gastrointestinal endoscopy 2012 Feb; 75(2).
Im GY, Modayil RJ, Lin CT, Geier SJ, Katz DS, Feuerman M, Grendell JH. The appendix may protect against Clostridium difficile recurrence. Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 2011 Dec; 9(12).
Im GY, Stavropoulos SN, Schrope BA. An unusual cause of pancreatitis. Gastroenterology 2011 Dec; 141(6).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Im did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.